IMCC
IM CannabisIMCC
IMCC
About: IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority is from Israel.
Employees: 55
0
Funds holding %
of 7,407 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
11% more funds holding
Funds holding: 9 [Q3] → 10 (+1) [Q4]
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
2.09% less ownership
Funds ownership: 6.0% [Q3] → 3.91% (-2.09%) [Q4]
10% less capital invested
Capital invested by funds: $316K [Q3] → $284K (-$31.9K) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for IMCC.
Financial journalist opinion
Based on 4 articles about IMCC published over the past 30 days
Neutral
PRNewsWire
1 week ago
IM Cannabis Provides Corporate Updates
TORONTO and GLIL YAM, Israel , April 11, 2025 /PRNewswire/ -- IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) (the "Company", "IM Cannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, today announced the following corporate updates. Nasdaq Notification Letter The Company has received a written notification (the "Notification Letter") from the Nasdaq Stock Market LLC ("Nasdaq") dated April 9, 2025, notifying the Company that it is no longer in compliance with Nasdaq Listing Rule 5550(b)(1).
Neutral
Seeking Alpha
2 weeks ago
IM Cannabis Corp. (IMCC) Q4 2024 Earnings Call Transcript
IM Cannabis Corp. (NASDAQ:IMCC ) Q4 2024 Earnings Conference Call March 31, 2025 9:00 AM ET Company Participants Anna Taranko - Director of Investor and Public Relations Oren Shuster - Chairman and Chief Executive Officer Uri Birenberg - Chief Financial Officer Conference Call Participants Aaron Grey - Alliance Global Partners Operator Good morning and welcome to IM Cannabis' Fourth Quarter and Full Year 2024 Earnings Conference Call. Today's conference call is being recorded.
Neutral
PRNewsWire
2 weeks ago
IM Cannabis Reports Fourth Quarter and Full Year 2024 Financial Results
Q4 2024 Caps a Year of Strategic and Operational Improvements for IMC with 25% Revenue Growth, 42% decrease in Operating Expenses, and $0.5M Adjusted EBITDA Profit TORONTO and GLIL YAM, Israel , March 31, 2025 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ: IMCC) (CSE: IMCC), an international medical cannabis company, is pleased to announce its financial results for the fourth quarter and year ended December 31, 2024. Unless otherwise stated, all amounts are reported in Canadian dollars and are compared to the quarter ended December 31, 2023.
Neutral
PRNewsWire
4 weeks ago
IM Cannabis to Report Fourth Quarter and Full Year 2024 Financial Results on Monday, March 31 2025 at 9:00am ET
TORONTO and GLIL YAM, Israel , March 20, 2025 /PRNewswire/ -- IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) (the "Company," "IMCannabis," or "IMC"), a leading medical cannabis company with operations in Israel and Germany, will report operational and financial results for the fourth quarter and full year 2024 ended December 31, 2024, on Monday, March 31, 2025 before the market opens. The Company will host a zoom web conference on the same day at 9:00a.m.
Neutral
PRNewsWire
3 months ago
IM Cannabis Announces Change of Auditors
TORONTO and GLIL YAM, Israel, Jan. 17, 2025 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ: IMCC) (CSE: IMCC), a leading medical cannabis company with operations in Israel and Germany, announces that it has changed its auditor from Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global (the "Predecessor Auditor") to Fahn Kanne & Co. Grant Thornton Israel (the "Successor Auditor") effective January 16, 2025. The Predecessor Auditor resigned effective January 16, 2025, at the Company's request, and the Company's board of directors, upon the audit committee's recommendation, appointed the Successor Auditor to fill the resulting vacancy until the close of the next annual meeting of the Company's shareholders.
Neutral
Seeking Alpha
5 months ago
IM Cannabis Corp. (IMCC) Q3 2024 Earnings Call Transcript
IM Cannabis Corp. (NASDAQ:IMCC ) Q3 2024 Earnings Conference Call November 14, 2024 9:00 AM ET Company Participants Anna Taranko - Director of Investor and Public Relations Oren Shuster - Chief Executive Officer Uri Birenberg - Chief Financial Officer Conference Call Participants Operator Good morning, and welcome to IM Cannabis' Third Quarter 2024 Earnings Conference Call. Today's conference call is being recorded.
Neutral
PRNewsWire
5 months ago
IM Cannabis Reports Third Quarter Financial Results
IMC pairs a +12% increase in revenue with a -16% decrease in the total operating expenses, building a solid foundation to deliver in 2025. TORONTO and GLIL YAM, Israel , Nov. 14, 2024 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ: IMCC) (CSE: IMCC), an international medical cannabis company, announced its financial results today for the third quarter ended September 30, 2024.
Neutral
PRNewsWire
5 months ago
IM Cannabis to Report Third Quarter 2024 Financial Results on Thursday, November 14th at 9:00am ET
TORONTO and GLIL YAM, Israel , Nov. 6, 2024 /PRNewswire/ -- IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, will report operational and financial results for the third 2024 ended September 30, 2024, on November 14, 2024, before the market opens. The Company will host a zoom web conference on the same day at 9:00am ET to discuss the results, followed by a question-and-answer session for the investment community.
Neutral
PRNewsWire
6 months ago
IM Cannabis Announces up to US$1,613,000 Private Placement Offering Led by Management
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO and GLIL YAM, Israel , Oct. 4, 2024 /PRNewswire/ -- IM Cannabis Corp. ("IM Cannabis" or the "Company") (NASDAQ: IMCC) (CSE: IMCC), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that it intends to undertake a non-brokered private placement offering of up to US$1,613,000 through the sale of approximately 625,000 units (each, an "Unit") at a price per Unit (the "Offering Price") calculated on the basis of the deemed price per common shares in the capital of the Company (each, a "Share") equal to the 10-day volume weighted average price of the Shares on Canadian Securities Exchange (the "Exchange") ending on the trading day preceding October 3, 2024. Each Unit will be comprised of one Share and one Share purchase warrant (each, a "Warrant").
Neutral
PRNewsWire
6 months ago
IMC Germany Announces Outstanding Preliminary Q3, 2024 Performance with 50% Growth Over Q2
TORONTO and GLIL YAM, Israel , Oct. 2, 2024 /PRNewswire/ -- IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that the preliminary sales results in Germany by its German subsidiary, Adjupharm GmbH ("IMC Germany"), for the third quarter of 2024 have significantly exceeded expectations, showing a remarkable 50% increase in revenue compared to the second quarter, where IMC Germany sold about CAD$ 3.5M. This outstanding growth demonstrates IMC Germany's successful execution of its strategic initiatives and strong market demand for its products.
Charts implemented using Lightweight Charts™